s
CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer
26-07-2024, 14:31
SUZHOU, China, July 26, 2024 /PRNewswire/ — CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the European Commission (EC) has approved sugemalimab (Brand name: Cejemly®) in combination with platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small-cell lung […] L'articolo CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer proviene da La Ragione.
CONTINUA A LEGGERE
12
0
0
Guarda anche
La Ragione
01:43
Il Verona ribalta il Venezia e vince il derby 2-1
La Ragione
Ieri, 23:43
Il Napoli batte 3-1 il Como e conserva il primato solitario
La Ragione
Ieri, 21:43
Nuove nomine nel Consiglio di Amministrazione di AmCham Italy
La Ragione
Ieri, 21:43
Inaugurato a Catania e Palermo il Trofeo Coni Sicilia 2024
La Ragione
Ieri, 20:45